Versão HTML básica
381
Chronic myeloid leukemia treatment guidelines: Brazilian Association of Hematology, Hemotherapy and Cell Therapy. Brazilian Medical Association Guidelines Project – 2012
Rev Bras Hematol Hemoter. 2012;34(5):367-82
Philadelphia-Positive OR Granulocytic Leukemia, Chronic)
AND Imatinib AND (Time factors OR early OR late OR
delay*) AND Therapy/broad[filter])) OR ((Leukemia,
Myelogenous, Chronic, BCR-ABL Positive OR Leukemia,
Myeloid, Philadelphia-Positive OR Leukemia, Granulocytic,
Chronic OR Myeloid Leukemia, Chronic OR Chronic Myeloid
Leukemia OR Leukemia, Myelocytic, Chronic OR Chronic
Myelocytic Leukemia OR Leukemia, Myelogenous, Chronic
OR Myelogenous Leukemia, Ph1-Positive OR Leukemia,
Myeloid, Ph1 Positive OR Myelogenous Leukemia,
Chronic OR Myeloid Leukemia, Philadelphia-Positive OR
Granulocytic Leukemia, Chronic) AND Imatinib AND (Time
factors OR early OR late) AND Prognosis/broad[filter]))))
OR (((((Leukemia, Myelogenous, Chronic, BCR-ABL
Positive OR Leukemia, Myeloid, Philadelphia-Positive OR
Leukemia, Granulocytic, Chronic OR Myeloid Leukemia,
Chronic OR Chronic Myeloid Leukemia OR Leukemia,
Myelocytic, Chronic OR Chronic Myelocytic Leukemia
OR Leukemia, Myelogenous, Chronic OR Myelogenous
Leukemia, Ph1-Positive OR Leukemia, Myeloid, Ph1 Positive
OR Myelogenous Leukemia, Chronic OR Myeloid Leukemia,
Philadelphia-Positive OR Granulocytic Leukemia, Chronic))
AND Imatinib)) AND therapy/narrow[filter])
PICO 9
Does the cytogenetic evaluation have an impact on prognosis?
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR
Leukemia, Myeloid, Philadelphia-Positive OR Leukemia,
Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR
Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic
OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous,
Chronic OR Myelogenous Leukemia, Ph1-Positive OR
Leukemia, Myeloid, Ph1 Positive OR Myelogenous Leukemia,
Chronic OR Myeloid Leukemia, Philadelphia-Positive OR
Granulocytic Leukemia, Chronic) AND (Cytogenetic Analysis
OR Cytogenetic*) AND ((sensitiv*[Title/Abstract] OR
sensitivity and specificity[MeSH Terms] OR diagnos*[Title/
Abstract] OR diagnosis[MeSH:noexp] OR diagnostic
*[MeSH:noexp] OR diagnosis, differential[MeSH:noexp] OR
diagnosis[Subheading:noexp]) OR (prognos*[Title/Abstract]
OR (first[Title/Abstract] AND episode[Title/Abstract]) OR
cohort[Title/Abstract])) OR (evaluation study OR comparative
study OR epidemiologic methods))
PICO 10
Does molecular evaluation by quantitative real time
polymerase chain reaction (PCR) have an impact on
prognosis?
((Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR
Leukemia, Myeloid, Philadelphia-Positive OR Leukemia,
Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR
Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic
OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous,
Chronic ORMyelogenous Leukemia, Ph1-Positive ORLeukemia,
Myeloid, Ph1 Positive OR Myelogenous Leukemia, Chronic
OR Myeloid Leukemia, Philadelphia-Positive OR Granulocytic
Leukemia, Chronic) AND (Polymerase Chain Reaction OR
PCR OR Nested PCR OR Anchored PCR) AND molecular
AND (prognos*[Title/Abstract] OR (first[Title/Abstract] AND
episode[Title/Abstract]) OR cohort[Title/Abstract]))
PICO 11
Can cytogenetics be replaced by quantitative PCR (qPCR) to
monitor CML patients taking tyrosine kinase inhibitors who
attained complete cytogenetic response?
((Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR
Leukemia, Myeloid, Philadelphia-Positive OR Leukemia,
Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR
Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic
OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous,
Chronic OR Myelogenous Leukemia, Ph1-Positive OR
Leukemia, Myeloid, Ph1 Positive OR Myelogenous Leukemia,
Chronic OR Myeloid Leukemia, Philadelphia-Positive OR
Granulocytic Leukemia, Chronic) AND (Cytogenetic Analysis OR
Cytogenetic*)) AND (Polymerase Chain Reaction OR PCR OR
Nested PCR OR Anchored PCR OR DNAMutational Analysis)
PICO 12
What is the treatment of choice for chronic-phase CML
patients resistant to Imatinib 400 mg?
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR
Leukemia, Myeloid, Philadelphia-Positive OR Leukemia,
Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR
Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic
OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous,
Chronic ORMyelogenous Leukemia, Ph1-Positive ORLeukemia,
Myeloid, Ph1 Positive OR Myelogenous Leukemia, Chronic
OR Myeloid Leukemia, Philadelphia-Positive OR Granulocytic
Leukemia, Chronic) AND imatinib AND ((clinical[Title/
Abstract] AND trial[Title/Abstract]) OR clinical trials[MeSH
Terms] OR clinical trial[Publication Type] OR random*[Title/
Abstract] OR random allocation[MeSH Terms] OR therapeutic
use[MeSH Subheading]) AND drug resistance
PICO 13
Are there differences in the toxicity profiles of second-
generation tyrosine kinase inhibitors (dasatinib and nilotinib)?
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR
Leukemia, Myeloid, Philadelphia-Positive OR Leukemia,
Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR
Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic
OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous,
Chronic ORMyelogenous Leukemia, Ph1-Positive ORLeukemia,
Myeloid, Ph1 Positive OR Myelogenous Leukemia, Chronic
OR Myeloid Leukemia, Philadelphia-Positive OR Granulocytic
Leukemia, Chronic) AND (dasatinib) AND (nilotinib) AND
(adverse effects OR complications OR safety OR toxicity) AND
(Therapy/broad[filter] OR comparative study OR epidemiologic
methods OR systematic[sb])